52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Rigel Pharmaceuticals Sees Q4 Revenue About $20.4 Mln
Rigel Sharpens Focus On Its Advanced Portfolio Opportunities
Rigel Reports Q3 2021 Financial Results
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The Company's research focuses on signaling pathways that are critical to disease mechanisms. The Company's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its clinical program, Fostamatinib is being studied in a Phase III trial for the treatment of warm autoimmune hemolytic anemia (wAIHA). The Company's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIP1) inhibitor program.
1180 Veterans Blvd
SOUTH SAN FRANCISCO, CA
Gary A. Lyons
Independent Chairman of the Board
Raul R. Rodriguez
President, Chief Executive Officer, Director
Dean L. Schorno
Chief Financial Officer, Executive Vice President
Dolly A. Vance
Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary
Executive Vice President and Chief Medical Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Eli Lilly will gain exclusive worldwide license to Rigel Pharmaceuticals Inc's autoimmune and inflammatory diseases treatment, including its lead candidate, R552, for potentially up to $960 million, the companies said on Thursday.
Eli Lilly and Co will gain exclusive worldwide license to Rigel Pharmaceuticals Inc's autoimmune and inflammatory diseases treatment candidate for potentially up to $960 million, the companies said on Thursday.
The U.S. National Institutes of Health on Thursday launched a clinical trial of fostamatinib, currently used to treat a blood platelet-destroying autoimmune disorder, in patients hospitalized with severe COVID-19, the disease caused by the novel coronavirus.
* RIGEL ANNOUNCES AVAILABILITY OF TAVLESSE® (FOSTAMATINIB DISODIUM HEXAHYDRATE) IN EUROPE
* RIGEL REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* RIGEL REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.